Perillyl alcohol causes G1 arrest through p15INK4b and p21 WAF1/Cip1 induction

Oncology Reports

Volumn 29, Issue 2, 2013, Pages 779-784

  Koyama, Makoto ^a   Sowa, Yoshihiro ^a   Hitomi, Toshiaki ^a   Iizumi, Yosuke ^a   Watanabe, Motoki ^a   Taniguchi, Tomoyuki ^a   Ichikawa, Masami ^a   Sakai, Toshiyuki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

G1 arrest; P15INK4b; P21WAF1 Cip1; Perillyl alcohol; Retinoblastoma protein

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2B; PERILLYL ALCOHOL; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CELL IMMORTALIZATION; CELL POPULATION; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; GENE INDUCTION; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPHOSPHORYLATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME INDUCTION; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; KERATINOCYTES; MONOTERPENES; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; RNA, SMALL INTERFERING;

EID: 84872766106     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2167     Document Type: Article

References (40)

1. Massague J: G1 cell-cycle control and cancer. Nature 432: 298-306, 2004. (Pubitemid 39551657)
2. Sherr CJ: Mammalian G1 cyclins. Cell 73: 1059-1065, 1993.
3. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A and Weinberg RA: Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73: 499-511, 1993. (Pubitemid 23143349)
4. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993. (Pubitemid 24036020)
5. Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512, 1999. (Pubitemid 29297917)
6. Roussel MF: The INK4 family of cell cycle inhibitors in cancer. Oncogene 18: 5311-5317, 1999. (Pubitemid 29462366)
7. Burkhart DL and Sage J: Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 8: 671-682, 2008.
8. Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA, Boone CW, Covey JM, Doody LA, Omenn GS, Greenwald P, Hong WK, Parkinson DR, Bagheri D, Baxter GT, Blunden M, Doeltz MK, Eisenhauer KM, Johnson K, Knapp GG, Longfellow DG, Malone WF, Nayfield SG, Seifried HE, Swall LM and Sigman CC: New agents for cancer chemo prevention. J Cellular Biochem (Suppl) 26: 1-28, 1996. (Pubitemid 27203750)
9. Crowell PL: Prevention and therapy of cancer by dietary monoterpenes. J Nutr 129: S775-S778, 1999.
10. Stark MJ, Burke YD, McKinzie JH, Ayoubi AS and Crowell PL: Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol. Cancer Lett 96: 15-21, 1995.
11. Shi W and Gould MN: Induction of differentiation in neuro-2A cells by the monoterpene perillyl alcohol. Cancer Lett 95: 1-6, 1995.
12. Mills JJ, Chari RS, Boyer IJ, Gould MN and Jirtle RL: Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res 55: 979-983, 1995.
13. Wagner JE, Huff JL, Rust WL, Kingsley K and Plopper GE: Perillyl alcohol inhibits breast cell migration without affecting cell adhesion. J Biomed Biotechnol 2: 136-140, 2002. (Pubitemid 44204510)
14. Loutrari H, Hatziapostolou M, Skouridou V, Papadimitriou E, Roussos C, Kolisis FN and Papapetropoulos A: Perillyl alcohol is an angiogenesis inhibitor. J Pharmacol Exp Ther 311: 568-575, 2004. (Pubitemid 39391541)
15. Shi W and Gould MN: Induction of cytostasis in mammary carcinoma cells treated with the anticancer agent perillyl alcohol. Carcinogenesis 23: 131-142, 2002. (Pubitemid 34213562)
16. Kip1 in human pancreatic adenocarcinoma cells. J Pharmacol Exp Ther 320: 1163-1170, 2007. (Pubitemid 46294051)
17. Haag JD and Gould MN: Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene. Cancer Chemother Pharmacol 34: 477-483, 1994. (Pubitemid 24306046)
18. Liu G, Oettel K, Bailey H, Ummersen LV, Tutsch K, Staab MJ, Horvath D, Alberti D, Arzoomanian R, Rezazadeh H, McGovern J, Robinson E, DeMets D and Wilding G: Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with meta-static androgen-independent prostate cancer. Invest New Drugs 21: 367-372, 2003. (Pubitemid 37486338)
19. Bailey HH, Attia S, Love RR, Fass T, Chappell R, Tutsch K, Harris L, Jumonville A, Hansen R, Shapiro GR and Stewart JA: Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother Pharmacol 62: 149-157, 2008. (Pubitemid 351537855)
20. da Fonseca CO, Simão M, Lins IR, Caetano RO, Futuro D and Quirico-Santos T: Efficacy of monoterpene perillyl alcohol upon the survival rate of patients with recurrent glioblastoma. J Cancer Res Clin Oncol 137: 287-293, 2011.
21. 2 synergistically induce apoptosis. Clin Cancer Res 16: 2320-2332, 2010.
22. INK4b in HDAC inhibitor-induced growth arrest. FEBS Lett 554: 347-350, 2003. (Pubitemid 37412512)
23. INK4b gene. FEBS Lett 576: 137-140, 2004. (Pubitemid 39330471)
24. INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Mol Cancer Ther 6: 1579-1587, 2007. (Pubitemid 46954025)
25. INK4b- inductive compound, as a novel MEK1/2 inhibitor. Cancer Sci 98: 1809-1816, 2007. (Pubitemid 47487919)
26. Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H and Sakai T: Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 241: 142-150, 1997. (Pubitemid 28033553)
27. Takagaki N, Sowa Y, Oki T, Nakanishi R, Yogosawa S and Sakai T: Apigenin induces cell cycle arrest and p21/WAF1 expression in a p53-independent pathway. Int J Oncol 26: 185-189, 2005.
28. WAF1/Cip1 and cell cycle arrest in a human osteosarcoma cell line. Int J Oncol 31: 915-922, 2007.
29. Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229, 2001. (Pubitemid 32695003)
30. Ink4a. Nature 448: 943-947, 2007.
31. Abbas T and Dutta A: p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400-414, 2009.
32. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A and Harlow E: New functional activities for the p21 family of CDK inhibitors. Genes Dev 11: 847-862, 1997. (Pubitemid 27175292)
33. Canman CE, Gilmer TM, Coutts SB and Kastan MB: Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 9: 600-611, 1995.
34. Abukhdeir AM and Park BH: p21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 10: e19, 2008.
35. Phillips LR, Malspeis L and Supko JG: Pharmacokinetics of active drug metabolites after oral administration of perillyl alcohol, an investigational antineoplastic agent, to the dog. Drug Metab Dispos 23: 676-680, 1995.
36. Ripple GH, Gould MN, Stewart JA, Tutsch KD, Arzoomanian R Z, Alberti D, Feierabend C, Pomplun M, Wilding G and Bailey HH: Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res 4: 1159-1164, 1998. (Pubitemid 28213326)
37. Ripple GH, Gould MN, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Binger K, Tutsch KD, Pomplun M, Wahamaki A, Marnocha R, Wilding G and Bailey HH: Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin Cancer Res 6: 390-396, 2000. (Pubitemid 30111455)
38. Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, Weiner LM, Langer CJ, Litwin S, Yeslow G, Halberr T, Qian M and Gallo JM: Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res 6: 3071-3080, 2000. (Pubitemid 30637730)
39. Sakai T: Molecular cancer epidemiology - the present status and future possibilities. Jpn J Hygiene 50: 1036-1046, 1996.
40. Sowa Y and Sakai T: Butyrate as a model for 'Gene-regulating chemoprevention and chemotherapy'. Biofactors 2: 283-287, 2000. (Pubitemid 32107417)